mDPR-Val-Cit-PAB-MMAE TFA

Cat. No.: HY-19813A

CAS No.: 2185872-76-6

Molecular Formula: $C_{67}H_{101}F_3N_{12}O_{17}$

Molecular Weight: 1403.58

Target: Drug-Linker Conjugates for ADC

Pathway: Antibody-drug Conjugate/ADC Related

Storage: -20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (71.25 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.7125 mL	3.5623 mL	7.1246 mL
	5 mM	0.1425 mL	0.7125 mL	1.4249 mL
	10 mM	0.0712 mL	0.3562 mL	0.7125 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition[1].

REFERENCES

[1]. Moquist, et al. Preparation of drug conjugates of IgG1 antibodies with self-stabilizing linkers having improved physiochemical properties for treating cancers and autoimmune diseases. World Intellectual Property Organization, WO2018031690 A1. 2018-02-15.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA